Literature DB >> 20144069

Beneficial effect of combination therapy comprising angiotensin II receptor blocker plus calcium channel blocker on plasma adiponectin levels.

Yukiko Inoue1, Tatsuyuki Kakuma, Yoshisuke Nonaka, Shunichiro Sumi, Keisuke Okamura, Sunao Kodama, Chie Ando, Hideya Niimura, Kei Miyoshi, Yoshihiro Tsuchiya, Yoshio Yamanouchi, Hidenori Urata.   

Abstract

The study aim was to examine the effect of combination therapy comprising angiotensin receptor blocker plus calcium antagonist on post-treatment plasma adiponectin levels compared to pretreatment levels. There was a significant gender difference in the relationship between preadiponectin level and age. In the search for contributing factors for treatment-based changes in adiponectin levels, these effects of gender and age were considered in statistical analysis. The adiponectin level in the combination therapy group was further increased compared to that in each of the monotherapy groups, despite there being no significant difference in antihypertensive effect, indicating that the combined medication provided an effect beyond that of lowering blood pressure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20144069     DOI: 10.3109/10641960902960516

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  2 in total

Review 1.  The role of adiponectin in endothelial dysfunction and hypertension.

Authors:  Edward Rojas; Daloha Rodríguez-Molina; Peter Bolli; Zafar H Israili; Judith Faría; Enzamaría Fidilio; Valmore Bermúdez; Manuel Velasco
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

2.  The influence of body mass index and renin-angiotensin-aldosterone system activity on the relationship between 25-hydroxyvitamin D and adiponectin in Caucasian men.

Authors:  Anand Vaidya; John P Forman; Patricia C Underwood; Paul N Hopkins; Gordon H Williams; Luminita H Pojoga; Jonathan S Williams
Journal:  Eur J Endocrinol       Date:  2011-03-14       Impact factor: 6.664

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.